LYCA.US Lycia Therapeutics, Inc. Common Stock
- Market cap
- USD 1.63B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LYCA.US undervalued?
Graham numberThe Graham number of Lycia Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lycia Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Lycia Therapeutics, Inc. Common Stock yet.
Lycia Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lycia Therapeutics, Inc. Common Stock
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of a…
Full company profileLycia Therapeutics, Inc. Common Stock financial statements
Lycia Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 14.9M | 6.74M |
| Operating Income | -32.5M | -39.9M |
| EBITDA | -25.3M | -35.5M |
| Net Income | -26.5M | -36.5M |
| Balance Sheet | ||
| Total Assets | 151M | 97.2M |
| Total Liabilities | 229M | 211M |
| Shareholders' Equity | -77.9M | -113M |
| Cash & Short-term Investments | 30.6M | 19.3M |
| Cash Flow | ||
| Operating Cash Flow | -29.5M | -51.4M |
| Capital Expenditure | 1.27M | 194K |
| Free Cash Flow | -30.8M | -51.6M |
| Ratios | ||
| ROA | -17.6% | -37.5% |
| Net Profit Margin | -177.4% | -540.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lycia Therapeutics, Inc. Common Stock dividends
Lycia Therapeutics, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Lycia Therapeutics, Inc. Common Stock
- Insiders 9.41%
- Institutions 46.68%
- Public & others 43.91%
- Shares outstanding 52.1M
- Free float 8.59M
Lycia Therapeutics, Inc. Common Stock company profile
- Company name
- Lycia Therapeutics, Inc. Common Stock
- Ticker
- LYCA.US
- Exchange
- USA Stocks
- Listed since
- Oct 23, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 31
- Fiscal year end
- December
- Address
- 400 East Jamie Court, South San Francisco, CA, United States, 94080
- Phone
- (650) 392-3357
- Website
- lyciatx.com
About Lycia Therapeutics, Inc. Common Stock
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Lycia Therapeutics, Inc. Common Stock management
10- Dr. Aetna Wun Trombley Ph.D.CEO, Secretary, President & Director · born 1979
- Dr. Steven Staben Ph.D.Chief Scientific Officer · born 1980
- Dr. Chin Hyok Lee M.D., M.P.H.Chief Medical Officer · born 1970
- Dr. Carolyn R. Bertozzi M.S., Ph.D.Founder & Chair of Scientific Advisory Board · born 1967
- Ms. Amy BachrodtChief Financial Officer · born 1979
- Dr. Karen E. Flick J.D., Ph.D.General Counsel, Corporate Secretary & Head of Intellectual Property · born 1969
- Mr. Darrin Lindhout Ph.D.VP & Head of Biologics
- Ms. Sofia Touami Ph.D.Chief Business Officer · born 1970
- Ms. Nadia Tchao M.D.VP & Head of Early Clinical Development
- Ms. Lynne Georgopoulos B.S., R.N.Senior VP & Head of Regulatory Affairs and Quality